Published data and treatment recommendations specific to the management of hereditary angioedema (HAE) in older patients (aged ≥65 years) are lacking.

The Berinert Patient Registry dataset included 27 older adults with HAE who used a combined total of 1701 Berinert (plasma-derived C1-inhibitor concentrate) infusions.

In this subset of older adults using Berinert for HAE, the rate of adverse events was low (0.02 events per infusion), and a majority of infusions (94.6 %) were administered outside of a healthcare setting, with no evidence of subjects having difficulty with home administration.